Gordon, Jason
Darlington, Oliver
McEwan, Phil
Lumley, Matthew
Taie, Amer
Hicks, Meagen
Charbonneau, Claudie
Blake, Angela
Hawkins, Neil
Goldenberg, Simon
Otter, Jonathan
Wilcox, Mark
Funding for this research was provided by:
Pfizer UK
Article History
First Online: 6 April 2020
Compliance with Ethical Standards
:
: All authors contributed to the model conception and design, and to drafting this manuscript. OD developed the model under supervision from JG and PME. Expert guidance was provided by SG, JO and MW throughout the model development process to ensure modelled relationships were appropriate and observed infection dynamics captured. NH provided expert guidance on modelling methods and approaches. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published. As the corresponding author, JG takes full responsibility for the work as a whole and the decision to submit and publish the manuscript.
: This study was funded by Pfizer.
: JG, OD and PM are employees of Health Economics and Outcomes Research Ltd., which received funding from Pfizer to undertake the research outlined in this study. AB, AT and CC are employees and stockholders of Pfizer, which provided funding for this study. MH was an employee and stockholder of Pfizer at the time this study was conducted and is now an employee of Johnson & Johnson. ML was an employee and stockholder of Pfizer at the time this study was conducted and is now an employee and stockholder of Moderna Therapeutics. NH received consulting fees related to this study. SG received consulting fees from Astellas, MSD, Shionogi and Pfizer. JO received consulting fees from Pfizer and Gama Healthcare. MW received consulting fees from AiCuris, Astra-Zeneca, Bayer, Cerexa, Durata, The Medicines Company, Menarini, Motif Biosciences, Nabriva, Paratek and Pfizer; lecture fees from Allergan, Astra-Zeneca and Pfizer; and grant support from Motif Biosciences, Nabriva, Paratek, Pfizer, Qpex Biopharma and VenatoRx.